The Effectiveness of Mesenchymal Stem Cell Therapy on COVID-19 Patients at Intensive Care Unit: Case Control StudyHayri Canbaz1, Ufuk Oğuz İdiz2, Hayriye Cankar Dal3, Fatih Kacıroğlu4, Seher Taş5, Hikmet Can Çubukçu6, Attila Bestemir7, Murat Gülşen8, İstemi Taha Polat9, Abubekir Laloğlu10, İbrahim Hakkı Tor11, Ekrem Akkurt12, Utku Ateş13, İsmail Reisli14, Esin Koç15, Ahmet Cağkan İnkaya16, Musa Karakükçü17, Mustafa Ceylan18, İbrahim C. Haznedaroğlu19, Haluk Akın201Yıldırım Beyazıt University, Yenimahalle Training and Research Hospital, Emergency Service, Ankara, Turkey
2University of Health Sciences Turkey, İstanbul Training and Research Hospital, Clinic of General Surgery, İstanbul, Turkey
3University of Health Sciences Turkey, Ankara City Hospital, Clinic of Intensive Care Unit, Ankara, Turkey
4General Directorate of Health Services, Head of Tissue, Organ Transplantation and Dialysis Services Department, Ankara, Turkey
5General Directorate of Health Services, Department of Tissue, Organ Transplantation and Dialysis Services, Organ Transplantation Unit, Ankara, Turkey
6Ankara University Stem Cell Institute, Interdisciplinary Stem Cells and Regenerative Medicine, Ankara, Turkey
7İstanbul Bakırköy Dr. Sadi Konuk Training and Research Hospital, Emergency Service, İstanbul, Turkey
8Ankara Dışkapı Yıldırım Beyazıt Training and Research Hospital, Clinic of Pediatrics, Ankara, Turkey
9Horasan State Hospital, Clinic of Anesthesiology and Reanimation, Ağrı, Turkey
10Atatürk University Faculty of Dentistry, Department of Oral, Dental and Maxillofacial Radiology, Erzurum, Turkey
11Erzurum City Hospital, Clinic of Anesthesiology and Reanimation, Erzurum, Turkey
12Konya Numune Hospital, Clinic of Physical Medicine and Rehabilitation, Konya, Turkey
13İstanbul Bilim University Faculty of Medicine, Department of Histology and Embryology, İstanbul, Turkey
14Necmettin Erbakan University Meram Medical Faculty Hospital, Department of Pediatric Immunology and Allergy, Konya, Turkey
15Gazi University Medical Faculty Hospital, Department of Pediatrics, Division of Neonatology, Ankara, Turkey
16Hacettepe University Medical Faculty Hospital, Department of Infectious Diseases, Ankara, Turkey
17Erciyes University Faculty of Medicine, Department of Pediatric Hematology and Oncology, Kayseri, Turkey
18Atatürk University Medical Faculty Hospital, Department of Neurology, Erzurum, Turkey
19Hacettepe University Medical Faculty Hospital, Department of Hematology, Ankara, Turkey
20Ege University Medical Faculty Hospital, Department of Medical Genetics, İzmir, Turkey
Objective: Many methods are used in the treatment of coronavirus disease 2019 (COVID-19), which causes acute respiratory distress syndrome (ARDS), and there are conflicting reports in the literature regarding the results of mesenchymal stem cell (MSC) therapy, which is one of those methods. The aim of our study is to evaluate the effect of MSC treatment applied together with standard treatments on survival.
Materials and Methods: This retrospective case-control study evaluates the survival effect of MSC treatment administered to patients treated in intensive care after the development of ARDS due to COVID-19 between March 2020 and March 2021. The age, gender, comorbid disease status, APACHE II score, and overall and comorbidity-based survival rates were compared between patients who received standard medical treatment (SMT) and patients who received MSC treatment together with SMT.
Results: There were 62 patients in the group receiving only SMT and 81 patients in the group receiving SMT and MSC. No difference was observed between the groups in terms of age, gender, presence of comorbid diseases, or APACHE II scores. There were also no differences according to Kaplan-Maier analysis for the survival statuses of the groups. There was no serious adverse effect due to MSC treatment among these patients.
Conclusion: Our study presents the largest case series in the literature, and it was observed that MSC treatment may not significantly affect overall survival or comorbid disease-based survival, in contrast to many other studies in the literature.
Keywords: COVID-19, Mesenchymal stem cell, Emergency, Mortality, Survival
Yoğun Bakım Ünitesindeki COVID-19 Hastalarında Mezenkimal Kök Hücre Tedavisinin EtkinliğiHayri Canbaz1, Ufuk Oğuz İdiz2, Hayriye Cankar Dal3, Fatih Kacıroğlu4, Seher Taş5, Hikmet Can Çubukçu6, Attila Bestemir7, Murat Gülşen8, İstemi Taha Polat9, Abubekir Laloğlu10, İbrahim Hakkı Tor11, Ekrem Akkurt12, Utku Ateş13, İsmail Reisli14, Esin Koç15, Ahmet Cağkan İnkaya16, Musa Karakükçü17, Mustafa Ceylan18, İbrahim C. Haznedaroğlu19, Haluk Akın201Yıldırım Beyazıt University, Yenimahalle Training and Research Hospital, Emergency Service, Ankara, Turkey
2University of Health Sciences Turkey, İstanbul Training and Research Hospital, Clinic of General Surgery, İstanbul, Turkey
3University of Health Sciences Turkey, Ankara City Hospital, Clinic of Intensive Care Unit, Ankara, Turkey
4General Directorate of Health Services, Head of Tissue, Organ Transplantation and Dialysis Services Department, Ankara, Turkey
5General Directorate of Health Services, Department of Tissue, Organ Transplantation and Dialysis Services, Organ Transplantation Unit, Ankara, Turkey
6Ankara University Stem Cell Institute, Interdisciplinary Stem Cells and Regenerative Medicine, Ankara, Turkey
7İstanbul Bakırköy Dr. Sadi Konuk Training and Research Hospital, Emergency Service, İstanbul, Turkey
8Ankara Dışkapı Yıldırım Beyazıt Training and Research Hospital, Clinic of Pediatrics, Ankara, Turkey
9Horasan State Hospital, Clinic of Anesthesiology and Reanimation, Ağrı, Turkey
10Atatürk University Faculty of Dentistry, Department of Oral, Dental and Maxillofacial Radiology, Erzurum, Turkey
11Erzurum City Hospital, Clinic of Anesthesiology and Reanimation, Erzurum, Turkey
12Konya Numune Hospital, Clinic of Physical Medicine and Rehabilitation, Konya, Turkey
13İstanbul Bilim University Faculty of Medicine, Department of Histology and Embryology, İstanbul, Turkey
14Necmettin Erbakan University Meram Medical Faculty Hospital, Department of Pediatric Immunology and Allergy, Konya, Turkey
15Gazi University Medical Faculty Hospital, Department of Pediatrics, Division of Neonatology, Ankara, Turkey
16Hacettepe University Medical Faculty Hospital, Department of Infectious Diseases, Ankara, Turkey
17Erciyes University Faculty of Medicine, Department of Pediatric Hematology and Oncology, Kayseri, Turkey
18Atatürk University Medical Faculty Hospital, Department of Neurology, Erzurum, Turkey
19Hacettepe University Medical Faculty Hospital, Department of Hematology, Ankara, Turkey
20Ege University Medical Faculty Hospital, Department of Medical Genetics, İzmir, Turkey
Amaç: Akut solunum sıkıntısı sendromuna (ARDS) neden olan koronavirüs hastalığı 2019 (COVID-19) tedavisinde birçok yöntem kullanılmakta olup, literatürde mezenkimal kök hücre (MSC) tedavisinin sonuçları ile ilgili çelişkili yayınlar bulunmaktadır. Çalışmamızın amacı standart tedavilerle birlikte uygulanan MSC tedavisinin sağkalım üzerine etkisini değerlendirmektir.
Gereç ve Yöntem: Bu retrospektif olgu kontrol çalışması, Mart 2020 ile Mart 2021 arasında COVID-19’a bağlı ARDS gelişmesi sonrası yoğun bakımda tedavi edilen hastalara uygulanan MSC tedavisinin sağkalım etkisini değerlendirmektedir. Çalışmada, standart medikal tedavi (SMT) alan hastalar ile SMT ile birlikte MSC tedavisi alan hastalar arasında yaş, cinsiyet, komorbid hastalık durumu, APACHE II skoru, genel ve komorbiditeye dayalı sağkalım oranları karşılaştırıldı.
Bulgular: Sadece SMT kullanan grupta 62 hasta, SMT ve MSC kullanan grupta 81 hasta vardı. Gruplar arasında yaş, cinsiyet, eşlik eden hastalık varlığı, Apache II skorları açısından fark gözlenmedi. Ayrıca grupların hayatta kalma durumları için Kaplan-Maier analizine göre herhangi bir farklılık yoktu. Hastalar arasında MSC tedavisine bağlı ciddi bir yan etki görülmedi.
Sonuç: Çalışmamız literatürdeki en geniş olgu serisine sahip olup, literatürdeki birçok çalışmadan farklı olarak MSC tedavisinin hem genel sağkalıma hem de komorbid hastalık temelli sağkalıma anlamlı bir etkisi olmadığı görülmüştür.
Anahtar Kelimeler: COVID-19, Mezenkimal kök hücre, Acil servis, Mortalite, Hayatta kalma
Hayri Canbaz, Ufuk Oğuz İdiz, Hayriye Cankar Dal, Fatih Kacıroğlu, Seher Taş, Hikmet Can Çubukçu, Attila Bestemir, Murat Gülşen, İstemi Taha Polat, Abubekir Laloğlu, İbrahim Hakkı Tor, Ekrem Akkurt, Utku Ateş, İsmail Reisli, Esin Koç, Ahmet Cağkan İnkaya, Musa Karakükçü, Mustafa Ceylan, İbrahim C. Haznedaroğlu, Haluk Akın. The Effectiveness of Mesenchymal Stem Cell Therapy on COVID-19 Patients at Intensive Care Unit: Case Control Study. Turk J Hematol. 2022; 39(4): 222-229
Corresponding Author: Hayri Canbaz, Türkiye |
|